

PI Major Mutations:None

PI Accessory Mutations:None

PR Other Mutations:T12TA 11.10%
n=1,763 • T127A 11.10%
n=1,763 • I13V 100%
n=1,763 • K14KR 11.10%
n=1,281 • E35D 100%
n=1,548 • M36I 100%
n=1,548 • R41K 100%
n=1,548 • R57K 10%
n=2,446 • L63T 100%
n=2,752 • H69K 10%
n=2,447 • L89M 100%
n=1,803

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

No drug resistance mutations were found for PI.

NRTI Mutations:None

NNRTI Mutations:[K103N](#) 10%
n=1,279

RT Other Mutations:E6D 10%
n=2,424 • V35T 100%
n=2,212 • E40D 10%
n=2,212 • V60I 100%
n=2,216 • K122E 10%
n=1,962 • D123N 100%
n=1,962 • K126KR 11.10%
n=1,282 • I135T 10%
n=1,674 • S162Y 100%
n=2,446 • K173S 10%
n=1,216 • Q174K 100%
n=1,216 • D177E 100%
n=1,216 • V179I 100%
n=1,200 • T200TA 11.10%
n=1,039 • I202V 100%
n=1,017 • Q207D 100%
n=1,038 • R211S 100%
n=1,079 • F214L 100%
n=1,527 • V245E 100%
n=1,513 • **E248EG** 11.10%
n=1,181 • D250E 10%
n=1,111 • K312R 100%
n=1,58 • S519N 100%
n=1,40 • Q524K 10%
n=1,41 • K527Q 10%
n=1,41 • E529D 100%
n=1,226 • A534S 100%
n=1,181 • A554AS 11.10%
n=1,039

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible	doravirine (DOR)	Susceptible
zidovudine (AZT)	Susceptible	efavirenz (EFV)	High-Level Resistance
stavudine (D4T)	Susceptible	etravirine (ETR)	Susceptible
didanosine (DDI)	Susceptible	nevirapine (NVP)	High-Level Resistance
emtricitabine (FTC)	Susceptible	rilpivirine (RPV)	Susceptible
lamivudine (3TC)	Susceptible		
tenofovir (TDF)	Susceptible		

RT comments

NNRTI

- K103N** is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.

Other

- V179I** is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

No drug resistance mutations were found for NRTI.

Drug resistance mutation scores of NNRTI:					
Download CSV					
Rule	DOR	EFV	ETR	NVP	RPV
K103N	0	60	0	60	0

INSTI Major Mutations:None

INSTI Accessory Mutations:None

IN Other Mutations:K14R 100%
n=1,388 • V32I 10%
n=1,128 • S39N 100%
n=1,114 • L45V 100%
n=1,152 • M50I 100%
n=1,102 • I72V 100%
n=1,107 • T112V 100%
n=1,052 • I113V 100%
n=1,052 • T124A 10%
n=1,046 • T125A 100%
n=1,046 • V126VF 11.10%
n=1,111 • G134D 100%
n=1,107 • I135V 100%
n=1,107 • D167E 100%
n=1,103 • V201I 100%
n=1,112 • K211R 100%
n=1,114 • N222K 100%
n=1,056 • L234I 100%
n=1,114 • S283G 100%
n=1,476

Integrase Strand Transfer Inhibitors	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Susceptible
raltegravir (RAL)	Susceptible

IN comments

Other

- M50I** is a highly polymorphic mutation, which has a prevalence of 3% to 34% in INSTI-naïve persons depending on subtype. It has been selected in vitro by DTG and BIC in combination with R263K. It may contribute to reduced DTG and CAB susceptibility in combination with R263K.

No drug resistance mutations were found for INSTI.